Insulin and diabetes drug manufacturers urged a federal judge again to dismiss 340B-related antitrust charges against them.

Drug Makers Ask Judge Again to Dismiss 340B-Related Antitrust Charges

Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.

AstraZeneca, Lilly, Novo Nordisk, and Sanofi filed their latest brief on Feb. 4 in New York state health center Mosaic Health and Virginia-based Central Virginia Health Services’ (CVHS) antitrust suit. U.S. Chief District Judge Elizabeth Wolford of U.S. District Court for the District of Western New York is hearing the case.

Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report